An Open Label, Single Dose, Phase I Study of the Excretion of Radioactivity, Metabolism and Pharmacokinetics Following Oral Administration of [14C]AZD2066 to Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2009
At a glance
- Drugs AZD 2066 (Primary)
- Indications Gastro-oesophageal reflux; Neuropathic pain
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 24 Feb 2009 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.
- 24 Feb 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 31 Jan 2009 New trial record